Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome
Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was re...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Kapoor, Kanika [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017 |
|---|
| Anmerkung: |
© Indian Academy of Pediatrics 2017 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Pediatrics - Springer-Verlag, 2010, 54(2017), 10 vom: Okt., Seite 885-886 |
|---|---|
| Übergeordnetes Werk: |
volume:54 ; year:2017 ; number:10 ; month:10 ; pages:885-886 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13312-017-1156-5 |
|---|
| Katalog-ID: |
SPR031292364 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR031292364 | ||
| 003 | DE-627 | ||
| 005 | 20230331071342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13312-017-1156-5 |2 doi | |
| 035 | |a (DE-627)SPR031292364 | ||
| 035 | |a (SPR)s13312-017-1156-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kapoor, Kanika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Indian Academy of Pediatrics 2017 | ||
| 520 | |a Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. | ||
| 700 | 1 | |a Saha, Abhijeet |4 aut | |
| 700 | 1 | |a Kaur, Manpreet |4 aut | |
| 700 | 1 | |a Dubey, Nand Kishore |4 aut | |
| 700 | 1 | |a Upadhyay, Ashish Datt |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Pediatrics |d Springer-Verlag, 2010 |g 54(2017), 10 vom: Okt., Seite 885-886 |w (DE-627)SPR031274943 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2017 |g number:10 |g month:10 |g pages:885-886 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13312-017-1156-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_72 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_131 | ||
| 912 | |a GBV_ILN_160 | ||
| 912 | |a GBV_ILN_376 | ||
| 912 | |a GBV_ILN_607 | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2017 |e 10 |c 10 |h 885-886 | ||
| author_variant |
k k kk a s as m k mk n k d nk nkd a d u ad adu |
|---|---|
| matchkey_str |
kapoorkanikasahaabhijeetkaurmanpreetdube:2017----:yohnltsdufrhlrnihrqetyeasnoseodee |
| hierarchy_sort_str |
2017 |
| publishDate |
2017 |
| allfields |
10.1007/s13312-017-1156-5 doi (DE-627)SPR031292364 (SPR)s13312-017-1156-5-e DE-627 ger DE-627 rakwb eng Kapoor, Kanika verfasserin aut Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2017 Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. Saha, Abhijeet aut Kaur, Manpreet aut Dubey, Nand Kishore aut Upadhyay, Ashish Datt aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 54(2017), 10 vom: Okt., Seite 885-886 (DE-627)SPR031274943 nnns volume:54 year:2017 number:10 month:10 pages:885-886 https://dx.doi.org/10.1007/s13312-017-1156-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 54 2017 10 10 885-886 |
| spelling |
10.1007/s13312-017-1156-5 doi (DE-627)SPR031292364 (SPR)s13312-017-1156-5-e DE-627 ger DE-627 rakwb eng Kapoor, Kanika verfasserin aut Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2017 Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. Saha, Abhijeet aut Kaur, Manpreet aut Dubey, Nand Kishore aut Upadhyay, Ashish Datt aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 54(2017), 10 vom: Okt., Seite 885-886 (DE-627)SPR031274943 nnns volume:54 year:2017 number:10 month:10 pages:885-886 https://dx.doi.org/10.1007/s13312-017-1156-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 54 2017 10 10 885-886 |
| allfields_unstemmed |
10.1007/s13312-017-1156-5 doi (DE-627)SPR031292364 (SPR)s13312-017-1156-5-e DE-627 ger DE-627 rakwb eng Kapoor, Kanika verfasserin aut Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2017 Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. Saha, Abhijeet aut Kaur, Manpreet aut Dubey, Nand Kishore aut Upadhyay, Ashish Datt aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 54(2017), 10 vom: Okt., Seite 885-886 (DE-627)SPR031274943 nnns volume:54 year:2017 number:10 month:10 pages:885-886 https://dx.doi.org/10.1007/s13312-017-1156-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 54 2017 10 10 885-886 |
| allfieldsGer |
10.1007/s13312-017-1156-5 doi (DE-627)SPR031292364 (SPR)s13312-017-1156-5-e DE-627 ger DE-627 rakwb eng Kapoor, Kanika verfasserin aut Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2017 Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. Saha, Abhijeet aut Kaur, Manpreet aut Dubey, Nand Kishore aut Upadhyay, Ashish Datt aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 54(2017), 10 vom: Okt., Seite 885-886 (DE-627)SPR031274943 nnns volume:54 year:2017 number:10 month:10 pages:885-886 https://dx.doi.org/10.1007/s13312-017-1156-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 54 2017 10 10 885-886 |
| allfieldsSound |
10.1007/s13312-017-1156-5 doi (DE-627)SPR031292364 (SPR)s13312-017-1156-5-e DE-627 ger DE-627 rakwb eng Kapoor, Kanika verfasserin aut Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Academy of Pediatrics 2017 Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. Saha, Abhijeet aut Kaur, Manpreet aut Dubey, Nand Kishore aut Upadhyay, Ashish Datt aut Enthalten in Indian Pediatrics Springer-Verlag, 2010 54(2017), 10 vom: Okt., Seite 885-886 (DE-627)SPR031274943 nnns volume:54 year:2017 number:10 month:10 pages:885-886 https://dx.doi.org/10.1007/s13312-017-1156-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 AR 54 2017 10 10 885-886 |
| language |
English |
| source |
Enthalten in Indian Pediatrics 54(2017), 10 vom: Okt., Seite 885-886 volume:54 year:2017 number:10 month:10 pages:885-886 |
| sourceStr |
Enthalten in Indian Pediatrics 54(2017), 10 vom: Okt., Seite 885-886 volume:54 year:2017 number:10 month:10 pages:885-886 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Indian Pediatrics |
| authorswithroles_txt_mv |
Kapoor, Kanika @@aut@@ Saha, Abhijeet @@aut@@ Kaur, Manpreet @@aut@@ Dubey, Nand Kishore @@aut@@ Upadhyay, Ashish Datt @@aut@@ |
| publishDateDaySort_date |
2017-10-01T00:00:00Z |
| hierarchy_top_id |
SPR031274943 |
| id |
SPR031292364 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031292364</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230331071342.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13312-017-1156-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031292364</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13312-017-1156-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kapoor, Kanika</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Academy of Pediatrics 2017</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Abhijeet</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaur, Manpreet</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dubey, Nand Kishore</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Upadhyay, Ashish Datt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Pediatrics</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">54(2017), 10 vom: Okt., Seite 885-886</subfield><subfield code="w">(DE-627)SPR031274943</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:885-886</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13312-017-1156-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_131</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_160</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_376</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_607</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield><subfield code="c">10</subfield><subfield code="h">885-886</subfield></datafield></record></collection>
|
| author |
Kapoor, Kanika |
| spellingShingle |
Kapoor, Kanika Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| authorStr |
Kapoor, Kanika |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR031274943 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Pediatrics |
| hierarchy_parent_id |
SPR031274943 |
| hierarchy_top_title |
Indian Pediatrics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR031274943 |
| title |
Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| ctrlnum |
(DE-627)SPR031292364 (SPR)s13312-017-1156-5-e |
| title_full |
Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| author_sort |
Kapoor, Kanika |
| journal |
Indian Pediatrics |
| journalStr |
Indian Pediatrics |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
txt |
| container_start_page |
885 |
| author_browse |
Kapoor, Kanika Saha, Abhijeet Kaur, Manpreet Dubey, Nand Kishore Upadhyay, Ashish Datt |
| container_volume |
54 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Kapoor, Kanika |
| doi_str_mv |
10.1007/s13312-017-1156-5 |
| title_sort |
mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| title_auth |
Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| abstract |
Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. © Indian Academy of Pediatrics 2017 |
| abstractGer |
Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. © Indian Academy of Pediatrics 2017 |
| abstract_unstemmed |
Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS. © Indian Academy of Pediatrics 2017 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_70 GBV_ILN_72 GBV_ILN_110 GBV_ILN_131 GBV_ILN_160 GBV_ILN_376 GBV_ILN_607 |
| container_issue |
10 |
| title_short |
Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome |
| url |
https://dx.doi.org/10.1007/s13312-017-1156-5 |
| remote_bool |
true |
| author2 |
Saha, Abhijeet Kaur, Manpreet Dubey, Nand Kishore Upadhyay, Ashish Datt |
| author2Str |
Saha, Abhijeet Kaur, Manpreet Dubey, Nand Kishore Upadhyay, Ashish Datt |
| ppnlink |
SPR031274943 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13312-017-1156-5 |
| up_date |
2024-07-03T23:02:00.135Z |
| _version_ |
1803600758189326336 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR031292364</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230331071342.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13312-017-1156-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR031292364</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13312-017-1156-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Kapoor, Kanika</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mycophenolate sodium for children with frequently relapsing or steroid dependent nephrotic syndrome</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Academy of Pediatrics 2017</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract In this retrospective study, patients with idiopathic frequentlyrelapsing nephrotic syndrome (FRNS) (n=27) and steroid dependent nephrotic syndrome (SDNS) (n=13) who received enteric coated mycophenolate sodium (ECMS) for at least 6 months, were included for analysis. Primary outcome was response to ECMS, which was defined as complete if there were no relapses, partial response if there was 1 relapse and no response if there were 2 or more relapses within 6 months of initiation. The mean (SD) dose of ECMS was 985.24 (190.82) mg/$ m^{2} $/day. Thirty patients(75%) had complete response, eight (20%) had partial and two (5%) patients did not respond at 6 months. ECMS seems to be a safe and effective as steroid sparing agent in children with FRNS/SDNS.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Abhijeet</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaur, Manpreet</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dubey, Nand Kishore</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Upadhyay, Ashish Datt</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Pediatrics</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">54(2017), 10 vom: Okt., Seite 885-886</subfield><subfield code="w">(DE-627)SPR031274943</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:54</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:885-886</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13312-017-1156-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_72</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_131</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_160</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_376</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_607</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">54</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield><subfield code="c">10</subfield><subfield code="h">885-886</subfield></datafield></record></collection>
|
| score |
7.4020653 |